Anti-KMT6 / EZH2 antibody [EPR9307(2)] - N-terminal
- RabMAb
- Recombinant
- KO Validated
- What is this?
2
(1 Review)
|
(59 Publications)
Rabbit Recombinant Monoclonal KMT6 / EZH2 antibody. N-terminal. Suitable for WB, ICC/IF, Flow Cyt (Intra), IHC-P and reacts with Mouse, Rat, Human samples. Cited in 59 publications.
View Alternative Names
KMT6, EZH2, Histone-lysine N-methyltransferase EZH2, ENX-1, Enhancer of zeste homolog 2, Lysine N-methyltransferase 6
- ICC/IF
Supplier Data
Immunocytochemistry/ Immunofluorescence - Anti-KMT6 / EZH2 antibody [EPR9307(2)] - N-terminal (AB191080)
Immunofluorescent analysis of HeLa cells (4% Paraformaldehyde-fixed; 0.1% tritonX-100-permeabilized) labeling KMT6 / EZH2 with ab191080 at 1/250 dilution followed by Goat anti rabbit IgG (AlexaFluor® 488) secondary at 1/200 dilution and counter-stained with DAPI (blue).
- Flow Cyt (Intra)
Lab
Flow Cytometry (Intracellular) - Anti-KMT6 / EZH2 antibody [EPR9307(2)] - N-terminal (AB191080)
ab191080 staining KMT6 / EZH2in the human cell line Jurkat (human acute T cell leukemia) by intracellular flow cytometry. Cells were fixed with 4% paraformaldehyde and the sample was incubated with the primary antibody at a dilution of 1/90. A goat anti rabbit IgG (Alexa Fluor® 488) at a dilution of 1/2000 was used as the secondary antibody.
Isoytype control : Rabbit monoclonal IgG (Black)
Unlabelled control : Cell without incubation with primary antibody and secondary antibody (Blue)
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-KMT6 / EZH2 antibody [EPR9307(2)] - N-terminal (AB191080)
Immunohistochemical analysis of paraffin-embedded Human breast carcinoma tissue labeling KMT6 / EZH2 with ab191080 at 1/250 dilution followed by pre-diluted HRP Polymer for Rabbit IgG secondary antibody and counter-stained with Hematoxylin (inset : negative control).
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
- WB
Lab
Western blot - Anti-KMT6 / EZH2 antibody [EPR9307(2)] - N-terminal (AB191080)
Lane 1 : Wild-type HAP1 cell lysate (20 μg)
Lane 2 : KMT6 / EZH2 knockout HAP1 cell lysate (20 μg)
Lane 3 : HEK293 cell lysate (20 μg)
Lane 4 : Ms testis tissue lysate (20 μg)
Lanes 1 - 4 : Merged signal (red and green). Green - ab191080 observed at 93 kDa. Red - loading control, ab8245, observed at 37 kDa.
ab191080 was shown to recognize KMT6 / EZH2 when KMT6 / EZH2 knockout samples were used, along with additional cross-reactive bands. Wild-type and KMT6 / EZH2 knockout samples were subjected to SDS-PAGE. ab191080 and ab8245 (loading control to GAPDH) were diluted at 1/500 and 1/10 000 respectively and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1/10 000 dilution for 1 h at room temperature before imaging.
All lanes:
Western blot - Anti-KMT6 / EZH2 antibody [EPR9307(2)] - N-terminal (ab191080)
Predicted band size: 85 kDa,92 kDa
false
- WB
Lab
Western blot - Anti-KMT6 / EZH2 antibody [EPR9307(2)] - N-terminal (AB191080)
Lane 1 : HEK293 cell lysate (20 μg)
Lane 2 : Mouse spleen tissue lysate (20 μg)
Lane 3 : Rat spleen tissue lysate (20 μg)
Lanes 1 - 3 : Merged signal (red and green). Green - ab191080 observed at 93 kDa. Red - loading control, ab8245, observed at 37 kDa.
Human, mouse and rat extracts were subjected to SDS-PAGE. ab191080 and ab8245 (loading control to GAPDH) were diluted at 1/500 and 1/10 000 respectively and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1/10 000 dilution for 1 h at room temperature before imaging.
All lanes:
Western blot - Anti-KMT6 / EZH2 antibody [EPR9307(2)] - N-terminal (ab191080)
Predicted band size: 85 kDa
Observed band size: 93 kDa
false
- WB
Lab
Western blot - Anti-KMT6 / EZH2 antibody [EPR9307(2)] - N-terminal (AB191080)
False colour image of Western blot : Anti-KMT6 / EZH2 antibody [EPR9307(2)] - N-terminal staining at 1/500 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab191080 was shown to bind specifically to KMT6 / EZH2. A band was observed at 90 kDa (green arrow) in wild-type MCF7 cell lysates with no signal observed at this size in ezh2 CRISPR-Cas9 edited cell line ab281611 (CRISPR-Cas9 edited cell lysate ab282963). The band observed in the CRISPR-Cas9 edited lysate lane below 90 kDa (yellow arrow) is likely to represent a truncated form of KMT6 / EZH2. This has not been investigated further and the functional properties of the gene product have not been determined. To generate this image, wild-type and ezh2 CRISPR-Cas9 edited MCF7 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution.
All lanes:
Western blot - Anti-KMT6 / EZH2 antibody [EPR9307(2)] - N-terminal (ab191080) at 1/1000 dilution
Lane 1:
Wild-type MCF7 cell lysate at 20 µg
Lane 2:
ezh2 CRISPR-Cas9 edited MCF7 cell lysate at 20 µg
Lane 3:
HEK-293 cell lysate at 20 µg
Lane 4:
Mouse Testis cell lysate at 20 µg
Observed band size: 90 kDa
false
- WB
CiteAb
Western blot - Anti-KMT6 / EZH2 antibody [EPR9307(2)] - N-terminal (AB191080)
KMT6 / EZH2 western blot using anti-KMT6 / EZH2 antibody [EPR9307(2)] - N-terminal ab191080. Publication image and figure legend from Xu, L., Feng, J., et al., 2020, Cell Death Dis, PubMed 32341332.
ab191080 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab191080 please see the product overview.
Effects of chidamide on expressions of histone-modifying enzymes (hMOF, SIRT1, and EZH2), and amounts of histone modifications (H4K16ac and H3K27me3) in MM cells.RPMI8226 and H929 cells were treated for 48 h with chidamide at the indicated concentrations. a, d The protein levels of SIRT1 (a), hMOF (b), or EZH2 (d) and amounts of H4K16ac (a) or H3K27me3 (d) were determined by immunoblot with the indicated antibodies. Both H3 and GAPDH were used as controls for protein loading. Blots shown are representative of three independent experiments. b, c, e Relative mRNA levels of SIRT1 (b), hMOF (c), and EZH2 (e) were detected by using quantitative RT-PCR. Mean ± SD of three independent experiments. *p < 0.05, compared with the treatment-naive control.
false
Related conjugates and formulations (2)
-
Anti-KMT6 / EZH2 antibody [EPR9307(2)] - BSA and Azide free
-
519 Alexa Fluor® 488
Alexa Fluor® 488 Anti-KMT6 / EZH2 antibody [EPR9307(2)]
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
EZH2 plays a central role in regulating gene expression during development and differentiation. It is a core component of the PRC2 complex which includes other proteins such as EED and SUZ12. Through its catalytic activity EZH2 contributes to the maintenance of the transcriptionally repressed state of genes influencing processes such as cell identity and proliferation. In many cell types EZH2-mediated gene silencing is necessary for normal development and dysregulation can lead to aberrant cellular processes.
Pathways
EZH2 participates in key regulatory networks notably the Wnt signaling pathway and the p53 pathway. Within the Wnt pathway EZH2's activity contributes to controlling gene expression that influences cellular differentiation and proliferation. Meanwhile interaction with the p53 pathway can impact the cellular response to stress and DNA damage highlighting EZH2’s regulatory dimension. Other proteins like β-catenin in the Wnt pathway interact with EZH2 reflecting its integration in these complex signaling networks.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (59)
Recent publications for all applications. Explore the full list and refine your search
Journal of applied oral science : revista FOB 33:e20250123 PubMed40498901
2025
Applications
Unspecified application
Species
Unspecified reactive species
Bone & joint research 14:143-154 PubMed39996291
2025
Applications
Unspecified application
Species
Unspecified reactive species
Inflammation 48:902-918 PubMed39052181
2024
Applications
Unspecified application
Species
Unspecified reactive species
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 11:e2400242 PubMed38874525
2024
Applications
Unspecified application
Species
Unspecified reactive species
Histology and histopathology 39:1371-1379 PubMed38567631
2024
Applications
Unspecified application
Species
Unspecified reactive species
Cytotechnology 76:231-246 PubMed38495291
2024
Applications
Unspecified application
Species
Unspecified reactive species
Nature communications 14:7884 PubMed38036539
2023
Applications
Unspecified application
Species
Unspecified reactive species
Experimental hematology & oncology 12:77 PubMed37679762
2023
Applications
Unspecified application
Species
Unspecified reactive species
Scientific reports 13:5363 PubMed37005451
2023
Applications
Unspecified application
Species
Unspecified reactive species
Renal failure 45:2149411 PubMed36724065
2023
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com